BaCkground
Natural Killer (NK)/T-cell lymphoma represents less than 5% of all lymphomas. It comes from NK cells, cytolytic lymphocytes of the innate immune system, responsible for immune responses to bacterial and viral infections. It is almost always (>95%) associated with the Epstein-Barr virus (EBV), 1 which plays an important role in the lymphomagenesis. Recently, Barrionuevo et al 2 and Kuo et aI 3 detected EBV-encoded small nuclear RNA (EBER-1) by in situ hybridisation in all the examined extranodal NK/T-cell lymphomas (ENKTCL).
NK/T-cell lymphoma arises more frequently in Asian countries and central/South America, but is a rare entity in North America and Europe, with an incidence of less than 1/1 000 000. 4 NK/T-cell lymphoma typically presents with involvement of the nasal cavity, nasopharynx, oropharynx and paranasal sinus as primary sites in more than 80% of the cases, referred to as 'nasaltype'. Even if most of the patients have the diagnosis at stage I/II, there is a high relapse rate after radiochemotherapy of more than 30%. 5 Extranasal sites include the gastrointestinal tract, skin, lung, liver, bone and testis. These two subgroups share similar histological and immunophenotypic features, expressing CD2, cytoplasmic CD3 epsilon, CD56 and TIA-1. Prognosis is worse in case of extranasal presentation and poor in relapsing and advanced stage patients.
Primary testicular lymphoma (PTL) is defined as the testis being the only involved site at presentation, without other nodal or organ involvement. 6 Diffuse large B-cell lymphoma (DLBCL) constitutes more than 70% of testicular lymphomas. Compared with DLBCL, testicular ENKTCL is a rare entity whether primary or secondary. 7 We report here a clinical case of a young patient presenting with multiple sinonasal relapses of an NK/T-cell lymphoma of the testis. Clinical, radiological presentation and the different modalities of treatment are presented.
CaSe preSenTaTion
A 35-year-old Caucasian man was investigated for a right testicular mass (measuring 5, 8×5, 3×4, 5 cm) in October 2015. Classical tumour markers for testicular cancer (LDH, APF and HCG) were negative. An orchiectomy was performed, and the diagnosis of ENKTCL was established. The immunohistochemistry showed a classical positivity for CD56, CD3, TIA-1 and EBER; CD5, CD7, CD8 and TdT were negative and the proliferation index was high with Mib-1 at 70%-80%. An initial radiological evaluation with PET-CT and bone marrow biopsy were performed that revealed a stage IE according to the Ann Arbor classification without any other nodal or extranodal localisation. Blood EBV PCR was low at 130 cop/mL (the normal detection threshold is less than 100 cop/mL). Fibroendoscopic examination of the nasal cavity was normal without any suspect lesions.
The patient was treated by radiation therapy with a total dose of 40 Gy in addition to concomitant chemotherapy (weekly cisplatin 30 mg/m²). This was followed by three cycles of chemotherapy according to the protocol SMILE (ddexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide). Radiological examination by a PET-CT 3 months post-treatment showed a complete remission of the disease. EBV PCR was still positive with 389 cop/mL. The patient presented with left-sided nasal obstruction 7 months post-treatment without any other rhinlogical symptoms. The fibroendoscopic examination of the nasal cavity showed a swelling of the mucosa at the level of the nasal cavity floor and lateral wall on both sides, predominating on the left side ( figure 1A) , with no evidence of any exophytic lesion. The CT, MRI and PET-CT rare disease imaging ( figure 2A,B) showed hypermetabolic activity of the nasal cavity on both side highly suggestive for recurrence; there was no evidence for testicular relapse and no other suspect nodal or extranodal lesion. Deep submucosal biopsies of the nasal cavity (figure 1B) confirmed the diagnosis of relapsing NK/Tcell lymphoma in the nasal cavity. The histological and immunohistochemistry results were similar to the primary disease of the right testis. The patient was treated by chemotherapy with three cycles according to the protocol GIDOX, (gemcitabine, ifosfamide, dexamethasone and oxaliplatin) followed by an intensification chemotherapy regimens according to the BEAM protocol (BCNU, etoposide, cytarabine and melphalan) and autologous stem-cell transplant. Radiological evaluation by PET-CT performed at the end of the treatment, showed complete response to the treatment without any residual metabolic activity or appearance of other suspect lesion ( figure 2C) . The endoscopic examination of the nasal cavity revealed a normal appearance of the mucosa.
Four months later, a routine clinical examination reveals a second relapse in the nasal cavity with the same swelling of the mucosa, confirmed by a new biopsy. The PET-CT showed only a small slightly hypermetabolic cervical node (negative for lymphoma on biopsy) ( figure 2D ). Local radiotherapy (40 Gy) of the nasal cavity and the cervical area was performed, followed by an allograft. The patient is currently still in remission, 2 years after the diagnosis of the first nasal relapse of the NK/T-cell lymphoma of the testis.
ouTCome and follow-up
Seven months after the treatment of a stage IE NK/T-cell lymphoma of the right testis, the patient presented a nasal relapse on the left side without a local recurrence or any other organ involvement. This relapse was treated with salvage chemotherapy and an autologous stem-cell transplantation.
Radiological and clinical evaluation at the end of the treatment of the nasal relapse showed a complete remission without any suspicious hypermetabolic activity on the PET-CT.
A routine follow-up 4 months after this remission showed a second nasal relapse on the left side with suspicion of involvement of the cervical lymph node on both sides (slightly hypermetabolic but negative for lymphoma at the biopsy) and without evidence of recurrence at the level of the testis or any other organ involvement. This new relapse was treated with locoregional radiotherapy At 2 years after the diagnosis of the first nasal relapse of the NK/T-cell lymphoma, the patient is still in remission.
diSCuSSion
We report the case of a primary extranasal ENKTCL of the testis in a young Caucasian man with twice nasal involvement as the unique site of relapse. Due to the relapse pattern, we decide to describe this case.
Few cases of primary testicular NK/T-cell lymphoma are reported in the literature. The largest series has been described recently by Huang et al 8 who collected 21 new cases in three hospitals in China. PTL represents 0.72% of all ENKTCL, during the study period. Most of the cases were Asian. Median age was 45 years. Seventy-three per cent were diagnosed at stage I/II. The 2-year overall survival of patients with de novo testicular NK/T-cell lymphoma was 34%, and the median survival was 15.3 months, putting forward the aggressiveness of this disease and the poor outcome. Even with stages I-II, the 2-year overall survival was 43%. In this review, sites of extratesticular involvement and relapse were lymph nodes, skin, contralateral testis, bone marrow, spleen, adrenal glands and the central nervous system. No nasal cavity was described as a site of relapse in those 21 cases.
Liang et al 9 reported earlier a series of 31 cases of testicular NK/T-cell lymphoma with 15 cases of primary and 16 cases of non-PTL. In the primary testicular cases, the secondary dissemination sites were the contralateral testis, lymph nodes, skin, spleen, central nervous system and liver; the nasopharynx was described as a unique site of relapse in only one case. In the 16 non-primary cases, 5 were secondary to nasal-type NK/T-cell lymphoma and 11 had initially multiple organ involvement, 2 of which having nasal cavity involvement.
The exact role of autologous stem-cell transplantation remains undefined in relapsing disease, however, it seems that our patient rare disease was in complete remission after salvage therapy. We, therefore, decided to add the stem-cell transplantation in order to offer him the maximum chance of durable response.
The prognosis of primary NK/T-cell lymphoma of the testis remains very poor and, even more so, in the nasal type. In a series of 101 patients of ENKTCL in Taiwan, published by Su et al, 5 5 years overall survival was 55% and 72% in patients with stages I-II. EBV DNA is a surrogate biomarker of the lymphoma load and should be followed during the course of the disease. 10 The two relapses in the nasal cavity in our patient raise questions as to the advanced stage of a primary nasal ENKTCL with infraclinical involvement of the nasal cavity, since deep biopsies were not undertaken initially. However, this case and those described in the series mentioned above showed the need to treat these patients very aggressively, similarly to advanced stages, with polychemotherapy-containing l-asparaginase, very active in this disease and high doses of methotrexate due to the high risk of brain relapse. 11 New treatment and new multimodal strategies of treatment should be investigated.
learning points
► Nasal relapse of a primary isolated natural killer (NK)/T-cell lymphoma of the testis is described for the first time, along with its presentation and applied treatment. ► Extranasal NK/T-cell lymphoma is a very rare clinical entity in Western countries and is always associated with the EpsteinBarr virus. ► Despite multimodal therapies, the prognosis is poor with very low survival rates.
